Global private equity firm Warburg Pincus has agreed to sell a 10.4 percent stake in NASDAQ-listed blood plasma-based biopharmaceutical company China Biologic Products in an underwritten public offering. Warburg Pincus, which originally invested in Biologic through Warburg Pincus Private Equity X, will sell 2.78 million shares. The offering is expected to close on or around 8 June 2016, subject to customary closing conditions.